Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction after Testosterone Replacement in Men with Type 2 Diabetes

Diabetes Care

Volumn 39, Issue 1, 2016, Pages 82-91

  Dhindsa, Sandeep ^a,b   Ghanim, Husam ^a   Batra, Manav ^a   Kuhadiya, Nitesh D ^a   Abuaysheh, Sanaa ^a   Sandhu, Sartaj ^a   Green, Kelly ^a   Makdissi, Antoine ^a   Hejna, Jeanne ^a   Chaudhuri, Ajay ^a   Punyanitya, Mark ^c   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Image Reading Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; LEPTIN; METFORMIN; PLACEBO; PROTEIN KINASE B BETA; SODIUM CHLORIDE; SULFONYLUREA DERIVATIVE; TESTOSTERONE CIPIONATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL1B PROTEIN, HUMAN; TESTOSTERONE; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; ADULT; AGED; AKT 2 GENE; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; GENE EXPRESSION; GLUCOSE INFUSION; GLUT4 GENE; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; HYPOGONADOTROPIC HYPOGONADISM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; IRBETA GENE; IRS 1 GENE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TREATMENT OUTCOME; UPREGULATION; BLOOD; BODY COMPOSITION; COMPLICATION; HYPOGONADISM; METABOLISM; MIDDLE AGED;

ADULT; BODY COMPOSITION; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-1BETA; INTRA-ABDOMINAL FAT; LEPTIN; MALE; MIDDLE AGED; SUBCUTANEOUS FAT; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961617337     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1518     Document Type: Article

References (41)

1. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462-5468
2. Dandona P, Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011;96: 2643-2651
3. Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 2006;29:2289-2294
4. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:3007-3019
5. Hamilton EJ, Gianatti E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011;74:377-383
6. Tsai EC, Matsumoto AM, Fujimoto WY, Boyko EJ. Association of bioavailable, free, and total testosterone with insulin resistance: Influence of sex hormone-binding globulin and body fat. Diabetes Care 2004;27:861-868
7. Gianatti EJ, Dupuis P, Hoermann R, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: A randomized controlled trial. Diabetes Care 2014;37:2098-2107
8. Jones TH, Arver S, Behre HM, et al.; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-837
9. Hackett G, Cole N, BhartiaM, Kennedy D, Raju J, Wilkinson P; BLAST Study Group. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST study. J Sex Med 2014;11:840-856
10. Grossmann M, Hoermann R, Wittert G, Yeap BB. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: A systematic review and meta-analysis of randomized controlled clinical trials. Clin Endocrinol (Oxf) 2015;83:344-351
11. Bhasin S, Cunningham GR, Hayes FJ, et al.; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559
12. Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male 2002;5:170-176
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
14. Lˆe KA, Ventura EE, Fisher JQ, et al. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care 2011;34:485-490
15. Korner J, Punyanitya M, Taveras C, et al. Sex differences in visceral adipose tissue postbariatric surgery compared to matched nonsurgical controls. Int J Body Compos Res 2008; 6:93-99
16. Salameh WA, Redor-Goldman MM, Clarke NJ, Reitz RE, Caulfield MP. Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: Total and free testosterone reference ranges. Steroids 2010;75:169-175
17. Dhindsa S, Furlanetto R, Vora M, Ghanim H, Chaudhuri A, Dandona P. Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care 2011;34:1854-1859
18. Söderg°ard R, Bäckstr öm T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-810
19. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672
20. Dandona P, Aljada A,Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an antiinflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265
21. Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C. A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl 2003;24:688-698
22. Wang C, Cunningham G, Dobs A, et al. Longterm testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098
23. Strotmeyer ES, Cauley JA, Schwartz AV, et al.; Health ABC Study.Diabetes is associated independently of body composition with BMD and bone volume in olderwhite and blackmen and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004;19:1084-1091
24. Frederiksen L, Højlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr) 2012;34:145-156
25. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003;52:2882-2887
26. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with noninsulin-dependent diabetes. J Clin Invest 1995;96:1261-1268
27. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002;277:42394-42398
28. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: Potential links with inflammation. Int J Obes Relat Metab Disord 2003;27(Suppl. 3):S6-S11
29. Byon JC, Kusari AB, Kusari J. Proteintyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem 1998;182:101-108
30. Kushner JA, Simpson L, Wartschow LM, et al. Phosphatase and tensin homolog regulation of islet growth and glucose homeostasis. J Biol Chem 2005;280:39388-39393
31. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism andmetabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495-3503
32. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73: 602-612
33. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": Results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014;2014:683515
34. Marin P, Holmäng S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res 1993;1:245-251
35. Marin P, Holmäng S, Jönsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992;16: 991-997
36. Marin P, Krotkiewski M, Björntorp P. Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues. Eur J Med 1992;1:329-336
37. Sattler F, He J, Chukwuneke J, et al. Testosterone supplementation improves carbohydrate and lipid metabolism in some older men with abdominal obesity. J Gerontol Geriatr Res 2014;3:1000159
38. Basu R, Dalla Man C, Campioni M, et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007;30:1972-1978
39. Tripathy D, Shah P, Lakshmy R, Reddy KS. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res 1998;30:642-645
40. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-733
41. Gopal RA, Bothra N, Acharya SV, et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 2010;16:570-576